SMN1 and proximal spinal muscular atrophy: Targeting SMN1‐AS using ASOs together with SMN2 splice‐switching oligonucleotides increases SMN expression in a dose‐dependent manner and improves survival in a severe mouse model of SMA (d’Ydewalle et al., 2017).